SOPH
SOPHiA GENETICS SA
NASDAQ · Healthcare · Medical - Healthcare Information Services · CH
$6.49
−3.57%Year over year
Reported trailing growth
- Revenue
- +23.6%
- EBITDA
- -18.7%
- EBIT
- -8.7%
- EPS
- -4.5%
- Free cash flow
- -2.6%
- Operating cash flow
- -13.3%
Forward estimates
Based on analyst estimates
- Revenue
- +29.8%
- EBITDA
- +53.7%
- EPS
- +43.3%
Three-year CAGR
- Revenue
- +17.6%
- EBITDA
- -26.9%
- EBIT
- -6.5%
- Net income
- -26.4%
- EPS
- -23.2%
- Free cash flow
- +24.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026